Jeffrey La Rosa

Stock Analyst at Leerink Partners

(0.09)
# 4,179
Out of 4,853 analysts
4
Total ratings
25%
Success rate
-38.53%
Average return

Stocks Rated by Jeffrey La Rosa

Janux Therapeutics
Dec 3, 2024
Maintains: Outperform
Price Target: $79$91
Current: $25.13
Upside: +262.12%
Pyxis Oncology
Jan 23, 2024
Initiates: Outperform
Price Target: $12
Current: $1.28
Upside: +837.50%
Merck & Co.
Oct 28, 2022
Maintains: Outperform
Price Target: $110$112
Current: $78.27
Upside: +43.09%